190 related articles for article (PubMed ID: 29148540)
1. Single-cell heterogeneity in ductal carcinoma in situ of breast.
Gerdes MJ; Gökmen-Polar Y; Sui Y; Pang AS; LaPlante N; Harris AL; Tan PH; Ginty F; Badve SS
Mod Pathol; 2018 Mar; 31(3):406-417. PubMed ID: 29148540
[TBL] [Abstract][Full Text] [Related]
2. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain.
Kalof AN; Tam D; Beatty B; Cooper K
J Clin Pathol; 2004 Jun; 57(6):625-9. PubMed ID: 15166269
[TBL] [Abstract][Full Text] [Related]
3. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C
Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835
[TBL] [Abstract][Full Text] [Related]
4. Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast.
Menezes MV; Cestari AL; Almeida O; Alvarenga M; Pinto GA; Gurgel MS; Souza GA; Zeferino LC
Sao Paulo Med J; 2006 May; 124(3):121-4. PubMed ID: 17119686
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
6. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?
Korsching E; Packeisen J; Liedtke C; Hungermann D; Wülfing P; van Diest PJ; Brandt B; Boecker W; Buerger H
J Pathol; 2005 Aug; 206(4):451-7. PubMed ID: 15906273
[TBL] [Abstract][Full Text] [Related]
7. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions.
Zagouri F; Sergentanis TN; Nonni A; Papadimitriou CA; Michalopoulos NV; Domeyer P; Theodoropoulos G; Lazaris A; Patsouris E; Zogafos E; Pazaiti A; Zografos GC
BMC Cancer; 2010 Jul; 10():353. PubMed ID: 20602789
[TBL] [Abstract][Full Text] [Related]
9. Differential distribution of ErbB-2 and pS2 proteins in ductal carcinoma in situ of the breast.
Inaji H; Koyama H; Motomura K; Noguchi S
Breast Cancer Res Treat; 1996; 37(1):89-92. PubMed ID: 8750531
[TBL] [Abstract][Full Text] [Related]
10. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma.
Leygue E; Snell L; Hiller T; Dotzlaw H; Hole K; Murphy LC; Watson PH
Cancer Res; 1996 Oct; 56(20):4606-9. PubMed ID: 8840971
[TBL] [Abstract][Full Text] [Related]
12. Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.
Barham W; Chen L; Tikhomirov O; Onishko H; Gleaves L; Stricker TP; Blackwell TS; Yull FE
BMC Cancer; 2015 Sep; 15():647. PubMed ID: 26424146
[TBL] [Abstract][Full Text] [Related]
13. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases.
Sneige N; Wang J; Baker BA; Krishnamurthy S; Middleton LP
Mod Pathol; 2002 Oct; 15(10):1044-50. PubMed ID: 12379750
[TBL] [Abstract][Full Text] [Related]
14. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
Paredes J; Lopes N; Milanezi F; Schmitt FC
Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast.
Perin T; Canzonieri V; Massarut S; Bidoli E; Rossi C; Roncadin M; Carbone A
Eur J Cancer; 1996 Jun; 32A(7):1148-55. PubMed ID: 8758245
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ.
Chade MC; Piato S; Galvão MAL; Aldrighi JM; Negrini R; Mateus EF; Medeiros EM
Einstein (Sao Paulo); 2018; 16(1):eAO4065. PubMed ID: 29694611
[TBL] [Abstract][Full Text] [Related]
17. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers.
Zhang RR; Man YG; Vang R; Saenger JS; Barner R; Wheeler DT; Liang CY; Vinh TN; Bratthauer GL
Breast Cancer Res; 2003; 5(5):R151-6. PubMed ID: 12927046
[TBL] [Abstract][Full Text] [Related]
18. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
[TBL] [Abstract][Full Text] [Related]
20. Usefulness and limitations of E-cadherin and β-catenin in the classification of breast carcinomas in situ with mixed pattern.
Gomes DS; Porto SS; Rocha RM; Gobbi H
Diagn Pathol; 2013 Jul; 8():114. PubMed ID: 23837653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
